Pfizer Inc said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co (NYSE:BHVN), making a big bet its ability to boost sales of the top-selling pill in a new class of migraine drugs.

​

**Source** : [ https://mosttraded.com/2022/05/10/pfizer-to-pay-11-6-billion-for-biohaven-to-tap-migraine-market/](https://mosttraded.com/2022/05/10/pfizer-to-pay-11-6-billion-for-biohaven-to-tap-migraine-market/)